Zurich Cantonal Bank
MRNS

Zurich Cantonal Bank’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Zurich Cantonal Bank’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-275
Closed -$147 – 2714
2024
Q4 		$147 Sell
275
-1,381
-83% -$962 ﹤0.01% 2640
2024
Q3 		$2.92K Sell
1,656
-27
-2% -$38 ﹤0.01% 2636
2024
Q2 		$1.97K Sell
1,683
-71
-4% -$178 ﹤0.01% 2631
2024
Q1 		$15.9K Sell
1,754
-834
-32% -$8.11K ﹤0.01% 2642
2023
Q4 		$28.1K Sell
2,588
-326
-11% -$2.44K ﹤0.01% 2643
2023
Q3 		$23.5K Sell
2,914
-946
-25% -$7.87K ﹤0.01% 2695
2023
Q2 		$41.9K Buy
+3,860
New +$33.1K ﹤0.01% 2651
2023
Q1 		– Sell
-2,327
Closed -$9.26K – 2884
2022
Q4 		$9.26K Hold
2,327
– – ﹤0.01% 2810
2022
Q3 		$15K Hold
2,327
– – ﹤0.01% 2840
2022
Q2 		$11K Sell
2,327
-282
-11% -$1.72K ﹤0.01% 2852
2022
Q1 		$24K Buy
+2,609
New +$25.9K ﹤0.01% 2652

Zurich Cantonal Bank's MRNS Position: Q1 2025 in Review

Zurich Cantonal Bank sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2025, closing a stake of 275 shares — an estimated $147 sold.

Zurich Cantonal Bank first reported a position in MRNS in Q1 2022 and held it in 11 quarters. The position peaked at $41.9K in Q2 2023. 0 funds tracked by Wall St. Rank hold MRNS as of Q1 2025.

  • Zurich Cantonal Bank reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2025 after selling out during the quarter.
  • Zurich Cantonal Bank sold 275 Marinus Pharmaceuticals, Inc shares in Q1 2025, an estimated $147.
  • Zurich Cantonal Bank first reported a position in Marinus Pharmaceuticals, Inc in Q1 2022 and held it in 11 quarters.
  • Zurich Cantonal Bank's Marinus Pharmaceuticals, Inc position peaked at $41.9K in Q2 2023.
  • 0 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2025.

Based on Zurich Cantonal Bank's 13F filing for Q1 2025, filed 7 May 2025.